Board Meeting-Outcome of Board Meeting
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 12 February 2018 had approved the Un-audited Financial Results of the Company for the quarter and nine months ended 31 December 2017. Please find enclosed herewith the following:... Un-Audited Financial Results For The Quarter/ Nine Months Ended 31 December 2017
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 12 February 2018 had approved the Un-audited Financial Results of the Company for the quarter and nine months ended 31 December 2017. Please find enclosed herewith the following:... Board Meeting On 12 February 2018
The meeting of the Board of Directors is scheduled to be held on Monday, the 12 February 2018 inter-alia to consider and approve the un-audited financial results of the Company for the quarter and nine months ended 31 December 2017. Further, in terms of provisions of the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the "Trading Window" of the Company shall remain closed from 04 February 2018 and will open... Shareholding for the Period Ended December 31, 2017
IOL Chemicals & Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Press Release / Media Release
Press Release for Financial Results and to invest Rs 200 crores in expanding its existing manufacturing capacities including its flagship product, Ibuprofen Dear Sirs, Please find enclosed herewith press release regarding Financial Result for the quarter and half year ended 30 September 2017 and to invest Rs 200 crores in expanding its existing manufacturing capacities including its flagship product, Ibuprofen for your information. Outcome of Board Meeting
The Board of Directors in its meeting held on 13 November 2017 had approved the following: 1.Un-audited Financial Results for the quarter and half year ended 30 September 2017. 2.To enhance the manufacturing capacity of Ibuprofen and enhance the capacities of backward integrated products with a project cost of Rs 200 crore which will be met through combination of equity, internal accruals and loans over a period of two years.... Disclosure Under Regulations 30 & 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dear Sir, Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 13 November 2017 had approved the following: 1. Un-audited Financial Results of the Company for the quarter and half year ended 30 September 2017. 2. To enhance the manufacturing capacity of Ibuprofen from 7200 TPA to 12000 TPA and enhance the... Board Meeting On 13 November 2017
The meeting of the Board of Directors is scheduled to be held on Monday, the 13th day of November, 2017 inter-alia to consider and approve the un-audited financial results of the Company for the quarter and half year ended 30 September 2017. Further, in terms of provisions of the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the "Trading Window" of the Company shall remain closed from 07 November 2017 and... Clarification
With reference to increase in Price, IOL Chemicals & Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed.